Accellix
Accellix was founded on the basis of creating a rapid, easy-to-use, automated cell phenotyping platform for point of need environments, focusing on cell therapy. Accellix is bringing next-generation analytical capabilities to its customers, enabling the measurement of critical quality attributes at every QC phenotyping interrogation point throughout the manufacturing process and the release of cell therapy products—when and where required. Currently, these assays are performed on standard flow cytometers in centralized labs which require skilled technicians, high maintenance, a separate lab space, and a long turnaround time. There is a growing need for simpler more automated technologies that can fit seamlessly into centralized and de-centralized point-of-need models. Accellix aims to bring the power of flow cytometry to the GMP manufacturing floor, automating the entire GMP cell phenotyping process from sample preparation to data analysis with the Accellix Platform. Accellix brings automated sample preparation, flow cytometry and data analysis directly into the manufacturing suite. The Accellix team is an interdisciplinary group composed of skilled biologists, engineers, mathematicians, technicians and more with deep experience in all aspects of cell therapy in general and the immunotherapy field. Accellix has growing offices in Jerusalem, Israel and San Jose, CA. At Accellix, our mission is to transform the status quo for quality control in the cell and gene therapy industry. We seek to establish ourselves as the New Gold Standard for QC through our Accellix Platform, a compact, automated and easy-to-use platform, which will bring quick and accurate flow cytometry capabilities that can directly integrate into GMP manufacturing workflows and at other point-of-need environments. By simplifying and standardizing the cellular analysis process, saving time and effort, the Accellix Platform will enable our partners in the growing field of cell and gene therapy to ensure the measurement of critical quality parameters of their cellular therapies, helping bring these life-saving treatments to patients in desperate need, faster than ever before. Our objective is to accelerate and elevate our customers’ ability to save lives with these transformative therapies.
